Opinion

Dec 4, 2024, 17:11

Iván R. González: Results from KEYNOTE-177 after 5 years by Thierry André et al.

Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:

“Results from KEYNOTE-177 after 5 years: innovation in treating metastatic colorectal cancer with MSI-H/dMMR. This study confirms the transformative impact of pembrolizumab as a first-line treatment, marking a turning point in oncologic care:

– Progression-free survival (PFS): 16.5 months with pembrolizumab vs. 8.2 months with chemotherapy (HR 0.60).
– Overall survival (OS): Median OS: 77.5 vs. 36.7 months (HR 0.73) and 5-year OS rates: 55% vs. 44%.
– Severe adverse events (AEs): Less frequent with pembrolizumab: 22% vs. 67%.

With sustained responses and lower toxicity, pembrolizumab doubles median OS, establishing itself as the standard of care for patients with MSI-H/dMMR metastatic colorectal cancer. This breakthrough redefines oncology practice.”

Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study

Authors: T. André, K.-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, E. Elez, D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D. Adelberg, L.A. Diaz, Jr

B.V. Jensen C. de la Fouchardière C.J.A. Punt cancer D. Adelberg D. Fogelman D. Smith D.T. Le E. Elez F. Rivera J. Alcaide-Garcia K.-K. Shiu L.A. Diaz L.H. Jensen OncoDaily Oncology P. Gibbs R. Garcia-Carbonero T. André T. Yoshino T.W. Kim Y. Zuo

365 Days of OncoDaily: Ending 2024 Strong

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Kimryn Rathmell: The year in cancer - 24 advances in 2024

Celebrating the Holiday Magic with Medical Community

Special Coverage